Novo Nordisk has launched the first GLP-1 weight-loss pill in the US at a lower price than injections.
The once-daily Wegovy pill is the only oral GLP-1 treatment currently available.
It follows US regulatory approval just before Christmas and is now on sale nationwide.
Self-pay patients can access the starting dose for $149 a month, far below injectable prices.
Injectable weight-loss drugs often cost more than $1,000 a month without insurance.
Novo hopes the pill’s lower price and needle-free format will attract more patients.
The launch intensifies competition with Eli Lilly, maker of rival obesity drugs.
Novo’s shares rose after the announcement, despite strong pressure from competitors.
The company aims to regain market share after profit warnings and restructuring last year.
Novo Nordisk Launches Wegovy Weight-Loss Pill in US, Intensifying Price Competition
Andrew Rogers
Andrew Rogers is a freelance journalist based in the USA, with over 10 years of experience covering Politics, World Affairs, Business, Health, Technology, Finance, Lifestyle, and Culture. He earned his degree in Journalism from the University of Florida. Throughout his career, he has contributed to outlets such as The New York Times, CNN, and Reuters. Known for his clear reporting and in-depth analysis, Andrew delivers accurate and timely news that keeps readers informed on both national and international developments.
Add A Comment
© 2026 Minsk Mirror. All Rights Reserved.